triage). The goal of this study is to determine factors associated with variability in the assessment and treatment of SCD patients presenting to the ED with acute pain.
Study Objectives: Flank pain secondary to renal colic is a common presentation to emergency departments (ED). Pain control for this malady varies widely, including the use of NSAID and opioid medications, the latter of which evoke several potential side effects and ethical considerations given the current national opioid epidemic. Emergency physicians are among the leaders in health care in recognizing and confronting the opioid epidemic, from acknowledgement of the problem to advocating for naloxone, PDMPs, and medication-assisted treatment. The Alternatives to Opiates (ALTO) program of St. Joseph's University Medical Center, for example, aims to mitigate the unnecessary use of opioids by providing a range of existing and innovative protocols for pain management. The primary study objective is to compare the analgesic efficacy of IV lidocaine to IV ketorolac for patients with known or suspected renal colic evaluated in a suburban tertiary medical center ED. We present an interim safety analysis as the protocol is halfway completed and still blinded, with enrollment of 30 out of a proposed 60 patients.
Methods: This is a prospective randomized double-blind cohort study. Patients are randomized by the inpatient pharmacy service to 2 groups: Group I receives acetaminophen 975 mg orally plus lidocaine 1.5 mg/kg via IV in 100 mL NS over 10 minutes while Group II receives acetaminophen 975 mg orally plus ketorolac 30 mg IV in 100 mL NS over 10 minutes. Primary study outcome is pain level using the 0-10 numeric rating scale measured at time 0 and at 5, 10, 15 and 30 minutes after medication administration. We set our goal sample size at 60 patients after determining a minimum of 50 patients with an alpha of 5% and difference of 6 units of change between treatments as the expected clinically significant change.
Results: With the blinded nature of the study protocol preserved, an interim safety analysis revealed that 7 of the 30 patients required rescue analgesia. None of the 30 patients experienced adverse effects from the medications administered.
Conclusions: An interim analysis revealed that 7 of 30 patients required rescue analgesia and none experienced any adverse effects from the medications received. Although a limited sample size, our study data suggests that IV lidocaine may be a reasonable alternative analgesic to opioids for the treatment of flank pain secondary to known or suspected renal colic, and with little increased risk of adverse medication effect.
NOTE: The views expressed are those of the author(s) and do not reflect the official policy of the Department of the Army, the Department of Defense or the U.S. Government.
Effectiveness and Safety of Droperidol in an Emergency Department in United States
Gaw CM, Cabrera D, Bellolio M, Mattson AE, Jeffery MM/Mayo Clinic, Rochester, MN Study Objectives: Droperidol is a dopamine D2 receptor antagonist, antipsychotic used extensively by emergency physicians, psychiatrists and anesthesiologists worldwide since 1967. It is an inexpensive, rapid-acting medication with a short half-life that functions as an analgesic, sedative, and antiemetic. It has been used for the treatment of headache, nausea, agitation, acute pain, chronic pain, pain in opiate-tolerance and multidrug-resistant abdominal pain. The United States Food and Drug Administration (FDA) issued a black box warning on the use of droperidol due to concerns of QT prolongation and potential fatal arrhythmias in 2001 after few case reports. Despite this, studies have found data supporting safe usage of low doses of droperidol, and its effectiveness in treating acute migraine headaches in the emergency department (ED) as well for sedation. The aim of this study was to evaluate the efficacy and safety of droperidol as an analgesic, antiemetic and sedative in a large cohort of patients presenting to the ED.
Methods: This was an observational cohort study of all droperidol administrations from 1/1/2012 through 4/19/2018 at an academic adult and pediatric ED with 77,000 annual ED visits located in United States. The primary endpoint was mortality within 24 hours of droperidol administration. Secondary endpoints included use of additional analgesia after the use of droperidol, called "rescue analgesia." We collected data on patient's date of visit, age, current medications, date and time of droperidol administration, any other medications administered in the same ED visit, chief complaint and final diagnosis. All patients who received droperidol were evaluated for the mortality and safety data. Among the patients who received droperidol for analgesia, we quantified those who required rescue analgesia 30 to 60 minutes after the first administration of droperidol. We adhere to the STrengthening the Reporting of OBservational studies in Epidemiology (STROBE) guidelines.
Results: A total of 6,881 patients received droperidol at our ED from January 2012 until April 2018. Reasons for administration were analgesic (N¼5,426, 78.9%), sedative (N¼599, 8.7%), and anti-emetic (N¼856, 12,4%). Zero deaths were recorded within 24 hours of droperidol administration from the entire sample of patients who received droperidol in the ED. Need for rescue analgesic medication was relatively rare, with 4.5% of patients with pain complaints receiving 1 or more analgesics 30 to 60 minutes after droperidol (N¼244). Less than 2% of pain patients received rescue opioids (N¼104) after receiving droperidol.
Conclusions: The development of novel pain management strategies is a national priority due to the opiate epidemic. There were no cases of fatal arrhythmias among these almost 7,000 pediatric and adult patient cohort. Our findings suggest droperidol is a safe and effective opiate sparing analgesic in the ED.
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Association of CYP2C9 and CYP2D6 Genotypes With Frequency of Emergency Department Visits for Sickle Cell Disease Acute Pain Vasoocclusive Crisis Lyon M, Jaja C, James E, Xu H, Kuchinski A, Kutlar A, Gibson R/Augusta University, Augusta, GA; University of Cincinatti, Cincinatti, OH Study Objectives: Acutely painful vasoocclusive crisis (VOC) is the hallmark symptom of sickle cell disease (SCD). While some patients are able to treat VOC pain with NSAIDs and oral narcotics at home and rarely use the emergency department (ED) for parenteral opioids, some patients use the ED frequently for opioid doses that often exceed ED guidelines. Some patients may experience suboptimal analgesics therapy. Others may be stigmatized as "frequent filers" or "drug seekers," particularly when their pain cannot be objectively quantified. In this study, we examined whether CYP2C9 and CYP2C6 genotypes based on 14 allelic variants with pharmacogenetic effects on analgesic drug metabolism are associated with frequency of visits for VOC pain in a dedicated SCD ED observation pathway program.
Methods: Genomic DNA from 131 adult unrelated patients with SCD was genotyped for 6 CYP2C9 alleles and 8 CYP2D6 alleles using the Sequenom Iplex Gold Reagent Kit. Theoretic metabolic profiles were based on published genetic data. We determined frequency of ED visits, including ED visits by patients ineligible for the dedicated SCD ED observation pathway due to opioid-related infractions. Based on the number of annual ED visits averaged over 5 years subjects were categorized as nonusers (0 visits/year), rare-users (0-1.0 visits/year), frequent users (1.1-3.9 visits/year), or high-users (4 visits/year). Statistical analysis was performed using a chi-square test with significance set at p<0.05.
Results: We reported genotype frequencies as homozygous wild-type, heterozygous, and homozygous variant/compound heterozygous; and the theoretic phenotypes as extensive, intermediate, ultra-rapid, and poor metabolizers. The combined frequency of the CYP2C9 and CYP2D6 allelic variants were 0.072 and 0.302 respectively. 14% percent of the subjects were intermediate metabolizers for the CYP2C9; while 30% and 2% were intermediate and poor metabolizers respectively for the CYP2D6. For 36 subjects with 3 or more ED visits, 11 were heterozygous for impaired metabolic profiles, and 2 were homozygous for impaired metabolic profiles for the 2 genes. Of 15 patients deemed ineligible for ED observation pathway visits; 4 were heterozygous for impaired metabolic profiles and 1 was homozygous for impaired metabolic profiles for the 2 genes. Seven CYP2C9 and 20 CYP2D6 genotypes were indeterminate for the cohort. Weak associations were observed between CYP2C9 and CYP2D6 and ED visit types (p¼0.75 and p¼0.48 respectively).
Conclusions: The concept of preemptive pharmacogenetics is a logical step toward identifying SCD patients with impaired drug metabolic capacities or likely to be refractory to current analgesic regimens. The integration of knowledge of genes involved in differential opioid metabolism into extant SCD standards of care could be helpful in rationalizing therapeutic practices and reducing ED visits for VOC pain. Study Objectives: Though EDs only account for 4% of total opioid prescriptions, recent evidence suggests that exposure to prescription opioids in the ED increases the risk of long-term opioid use. It is unclear if this finding generalizes to populations outside of fee-for-services Medicare. We use methods similar to a recent study to determine if quasi-random exposure to high or low intensity opioid prescribers in the ED influences the risk of long-term opioid use in a mixed age population served by a large managed care network.
Methods: We performed a retrospective analysis of clinical and administrative data for adult Kaiser Permanente Southern California members who presented to 1 of 14 EDs between January 2013 and December 2014. Only patients continuously enrolled in the Kaiser medical plan for at least 6 months prior to their index ED visit and 1 year following the index ED visit. We categorized ED providers according to the proportion of patients to whom they prescribed opioids at each hospital and stratified them into quartiles. Accordingly, "high" intensity prescribers are the quartile of providers who are most likely to prescribe opioids to their ED patients at any given hospital. The primary outcome was long-term opioid use, defined as a patient filling at least 90 days supply of opioids in the 12 months following the index visit. The analysis focused on opioidnaïve patients, defined as the patient having no opioid prescription in the 6 months preceding the ED visit. We test the hypothesis that treatment by high intensity prescribers is associated with higher odds of long term use (compared with treatment by low intensity prescribers) using multivariate logistic regression controlled for observable patient covariates (eg, age, race, diagnosis, sex, triage acuity, pain score) and hospital characteristics. Because ED patients generally cannot choose whether they are treated by a "high" or "low" intensity prescriber in an ED setting, the results are less likely to be confounded by selection bias.
Results: We identified 72,838 patients treated by "low intensity" prescribers and 94,192 treated by "high intensity" providers. High intensity opioid providers gave opioid prescriptions to 29.3% of their ED encounters compared to only 8.5% of the low intensity providers. However, there was no significant association between treatment by high versus low intensity prescribers on the key outcome of long-term opioid use among opioid-naïve patients (OR 1.02 95% CI 0.853-1.219). High comorbidity index (OR 3.5, 95% CI 3.2-3.9), high maximal pain score (OR 1.9, 95% CI 1.8-2.0) and advancing age were associated with higher risk of long-term opioid use.
Conclusions: We do not observe any association with ED exposure to high versus low intensity prescribers and long-term opioid use. These findings are in contrast to a recent analysis conducted in a fee-for-service Medicare population. Reasons for these disparate results require further study but may include that the managed care environment protects against this exposure, our data is more recent and attention to limiting opioid prescribing has recently intensified (2013-2014 versus 2008-2011) or that the effects of exposure to a high intensity provider are limited to older populations.
